A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Farrukh T Awan; Peter Hillmen; Andrzej Hellmann; Tadeusz Robak; Steven G Hughes; Denise Trone; Megan Shannon; Ian W Flinn; John C Byrd

doi:10.1111/bjh.13061

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Farrukh T Awan
, Peter Hillmen
, Andrzej Hellmann
, Tadeusz Robak
, Steven G Hughes
, Denise Trone
, Megan Shannon
, Ian W Flinn
, John C Byrd

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

28 Citations (Web of Science)

Original language	English
Pages (from-to)	466-477
Journal	BRITISH JOURNAL OF HAEMATOLOGY
Volume	167
Issue number	4
DOIs	https://doi.org/10.1111/bjh.13061
Publication status	Published - 2014

Keywords

INITIAL THERAPY
CD23
LYMPHOMA
CHEMOIMMUNOTHERAPY
EXPRESSION
APOPTOSIS
SURVIVAL
REGIMEN
CELLS
TRIAL

Access to Document

10.1111/bjh.13061

Cite this

Awan, F. T., Hillmen, P., Hellmann, A., Robak, T., Hughes, S. G., Trone, D., Shannon, M., Flinn, I. W., & Byrd, J. C. (2014). A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY , 167(4), 466-477. https://doi.org/10.1111/bjh.13061

Awan, Farrukh T ; Hillmen, Peter ; Hellmann, Andrzej et al. / A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. In: BRITISH JOURNAL OF HAEMATOLOGY 2014 ; Vol. 167, No. 4. pp. 466-477.

@article{81869183450b4399b1a41a3e25dc5c8c,

title = "A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.",

keywords = "INITIAL THERAPY, CD23, LYMPHOMA, CHEMOIMMUNOTHERAPY, EXPRESSION, APOPTOSIS, SURVIVAL, REGIMEN, CELLS, TRIAL",

author = "Awan, \{Farrukh T\} and Peter Hillmen and Andrzej Hellmann and Tadeusz Robak and Hughes, \{Steven G\} and Denise Trone and Megan Shannon and Flinn, \{Ian W\} and Byrd, \{John C\}",

year = "2014",

doi = "10.1111/bjh.13061",

language = "English",

volume = "167",

pages = "466--477",

journal = "BRITISH JOURNAL OF HAEMATOLOGY ",

issn = "0007-1048",

number = "4",

}

Awan, FT, Hillmen, P, Hellmann, A, Robak, T, Hughes, SG, Trone, D, Shannon, M, Flinn, IW & Byrd, JC 2014, 'A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.', BRITISH JOURNAL OF HAEMATOLOGY , vol. 167, no. 4, pp. 466-477. https://doi.org/10.1111/bjh.13061

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. / Awan, Farrukh T; Hillmen, Peter; Hellmann, Andrzej et al.
In: BRITISH JOURNAL OF HAEMATOLOGY , Vol. 167, No. 4, 2014, p. 466-477.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

AU - Awan, Farrukh T

AU - Hillmen, Peter

AU - Hellmann, Andrzej

AU - Robak, Tadeusz

AU - Hughes, Steven G

AU - Trone, Denise

AU - Shannon, Megan

AU - Flinn, Ian W

AU - Byrd, John C

PY - 2014

Y1 - 2014

KW - INITIAL THERAPY

KW - CD23

KW - LYMPHOMA

KW - CHEMOIMMUNOTHERAPY

KW - EXPRESSION

KW - APOPTOSIS

KW - SURVIVAL

KW - REGIMEN

KW - CELLS

KW - TRIAL

U2 - 10.1111/bjh.13061

DO - 10.1111/bjh.13061

M3 - Original Article

C2 - 25130401

SN - 0007-1048

VL - 167

SP - 466

EP - 477

JO - BRITISH JOURNAL OF HAEMATOLOGY

JF - BRITISH JOURNAL OF HAEMATOLOGY

IS - 4

ER -

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D et al. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY . 2014;167(4):466-477. doi: 10.1111/bjh.13061